Tags

Type your tag names separated by a space and hit enter

Omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease: do formulation, dosage & comparator matter?
Mo Med 2013 Nov-Dec; 110(6):495-8MM

Abstract

Multiple trials over the past two decades testing omega-3 polyunsaturated fatty acids (PUFAs), containing eicosapentaenoic acid (EPA) and or docosahexaenoic acid (DHA), have shown substantial benefits for reducing major coronary heart disease (CHD) events, all-cause mortality, cardiovascular (CV) death, sudden cardiac death (SCD), and stroke. However, recent trials testing omega-3s have generally failed to confirm these benefits. While increased fish and fish oil intake among the general population, increased use of optimal medical therapy (including statins, aspirin, and modern antihypertensive medications) probably make it more challenging for fish oil supplementation to show additional benefits, there might be further explanations in the formulation, dosage, and comparator used in these recent omega-3 trials.

Authors+Show Affiliations

Mid America Heart Institute, Saint Luke's Hospital, Kansas City, USA. jjdinicol@gmail.comHeart Hospital, University College London Hospitals UCLH, London-UK.Mid America Heart institute at Saint Luke's Hospital and University of Missouri-Kansas City, Kansas City, USA.

Pub Type(s)

Journal Article

Language

eng

PubMed ID

24564001

Citation

DiNicolantonio, James J., et al. "Omega-3 Polyunsaturated Fatty Acids for the Prevention of Cardiovascular Disease: Do Formulation, Dosage & Comparator Matter?" Missouri Medicine, vol. 110, no. 6, 2013, pp. 495-8.
DiNicolantonio JJ, Meier P, O'Keefe JH. Omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease: do formulation, dosage & comparator matter? Mo Med. 2013;110(6):495-8.
DiNicolantonio, J. J., Meier, P., & O'Keefe, J. H. (2013). Omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease: do formulation, dosage & comparator matter? Missouri Medicine, 110(6), pp. 495-8.
DiNicolantonio JJ, Meier P, O'Keefe JH. Omega-3 Polyunsaturated Fatty Acids for the Prevention of Cardiovascular Disease: Do Formulation, Dosage & Comparator Matter. Mo Med. 2013;110(6):495-8. PubMed PMID: 24564001.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Omega-3 polyunsaturated fatty acids for the prevention of cardiovascular disease: do formulation, dosage & comparator matter? AU - DiNicolantonio,James J, AU - Meier,Pascal, AU - O'Keefe,James H, PY - 2014/2/26/entrez PY - 2014/2/26/pubmed PY - 2014/4/18/medline SP - 495 EP - 8 JF - Missouri medicine JO - Mo Med VL - 110 IS - 6 N2 - Multiple trials over the past two decades testing omega-3 polyunsaturated fatty acids (PUFAs), containing eicosapentaenoic acid (EPA) and or docosahexaenoic acid (DHA), have shown substantial benefits for reducing major coronary heart disease (CHD) events, all-cause mortality, cardiovascular (CV) death, sudden cardiac death (SCD), and stroke. However, recent trials testing omega-3s have generally failed to confirm these benefits. While increased fish and fish oil intake among the general population, increased use of optimal medical therapy (including statins, aspirin, and modern antihypertensive medications) probably make it more challenging for fish oil supplementation to show additional benefits, there might be further explanations in the formulation, dosage, and comparator used in these recent omega-3 trials. SN - 0026-6620 UR - https://www.unboundmedicine.com/medline/citation/24564001/Omega_3_polyunsaturated_fatty_acids_for_the_prevention_of_cardiovascular_disease:_do_formulation_dosage_&_comparator_matter L2 - https://www.ncbi.nlm.nih.gov/pmc/articles/pmid/24564001/ DB - PRIME DP - Unbound Medicine ER -